The General Assembly of Pepric has appointed Dr. Enrico Bastianelli as independent non-executive Board member. Dr. Bastianelli is the CEO of Bone Therapeutics since 2006, a cell therapy company for bone fracture repair and prevention.
Previously, Dr. Bastianelli gained a tremendous expertise in the cell and pharmaceutical industry based on many years of experience at Procter and Gamble Pharmaceuticals, McKinsey & Co and ProSkelia.
“We are delighted to welcome Dr. Bastianelli to the Board of Pepric, developing instrumentation for cell and particle detection and imaging. His experience and profound understanding of the end-users market of Pepric’s technology will deliver substantial benefit in the decision making process.”, said Stephanie Teughels, CEO of Pepric.
Commenting on his appointment, Dr. Bastianelli said: “I’m pleased to join Pepric offering new solutions for targeted molecular imaging and longitudinal cell detection. I’m looking forward to contribute to its business strategy to maximize the potential of its innovative instruments.”